PD05-06 INFECTION PHENOTYPE IN INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME: DOES BACTERIAL-INDUCED MUCOSAL CELLULAR IMMUNE IMBALANCE HYPERSENSITIVITY EXPLAIN RESPONSE TO MV140 RECURRENT UTI VACCINE?
Bibliographic record
Abstract
You have accessJournal of UrologyCME1 Apr 2023PD05-06 INFECTION PHENOTYPE IN INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME: DOES BACTERIAL-INDUCED MUCOSAL CELLULAR IMMUNE IMBALANCE HYPERSENSITIVITY EXPLAIN RESPONSE TO MV140 RECURRENT UTI VACCINE? J. Curtis Nickel, Kerri-Lynn Kelly, Ashley Griffin, and R. Christopher Doiron J. Curtis NickelJ. Curtis Nickel More articles by this author , Kerri-Lynn KellyKerri-Lynn Kelly More articles by this author , Ashley GriffinAshley Griffin More articles by this author , and R. Christopher DoironR. Christopher Doiron More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003229.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: A subset of interstitial cystitis/bladder pain syndrome (IC/BPS) patients experience recurrent UTI (rUTI) associated with symptom flares. rUTI subjects with associated IC/BPS were enrolled in the First North American Early Clinical experience trial evaluating a new sublingual UTI preventative vaccine, MV140. Recent research shows that women with rUTI develop an imbalance in the T Helper 1 and 2 (Th2 over expression) in the bladder mucosa. Our study will suggest that this infection subcategory of IC/BPS patients develop a T Helper 2 (Th2)-type hypersensitivity (or allergy) to bacteria present in their urinary microbiome that responds to mucosal immune modulation. METHODS: Female participants with ≥3 documented UTI/year underwent a 3 month vaccination treatment period with a 9 month efficacy period after completion of vaccine treatment (total 12 months). There was no exclusion criteria for subjects in relation to baseline urinary symptoms and/or discomfort/pain. Primary outcome was no UTI following vaccination. Secondary outcomes included change in UTI incidence, overall patient reported subjective global assessment (responder defined as moderately or markedly improved on 7-point SGA scale) and safety. RESULTS: Sixteen subjects with IC/BPS related symptoms and rUTI (mean age 46.6; range 23-74 years; mean number of UTI in previous year 6.1+/-4.2) were eligible to be included in the Health Canada approved MV140 vaccine study for prevention of rUTI. All subjects completed the 3 month vaccination period. One subject lost to followup after 6 month visit. Six subjects were UTI-free while all 16 subjects had a reduction in UTI compared to the year pre-vaccination. The total post-vaccination reduction in UTI compared to pre-vaccination was 80% (0.1 UTI/subject/month from 0.5 UTI/subject/month respectively) At 12 months, 13 subjects (81.3%) were SGA responders (moderately or markedly improved) and the responders reported a reduction in IC/BPS symptoms with 8 subjects reporting significant or almost complete resolution of their specific long-term bladder discomfort/pain and bothersome urinary frequency or urgency. Four subjects reported mild and self limited adverse events during vaccination period but none were related to MV140 vaccine. CONCLUSIONS: Sublingual MV140 vaccine in IC/BPS patients with rUTI not only report UTI-free or reduced UTI incidence status but also after approximately 9 months post vaccination, many have resolution of their-long term treatment refractory IC/BPS symptoms. This suggests some cases of IC/BPS may be etiologically based on a Th2 cell type hypersensitivity to bacteria within or entering the urinary microbiome that responds to a vaccine whose mechanism of action is to normalize or balance the bladder Th1/Th2 mucosal immune system. Source of Funding: Inmunotek provided MV140 vaccine © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e150 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information J. Curtis Nickel More articles by this author Kerri-Lynn Kelly More articles by this author Ashley Griffin More articles by this author R. Christopher Doiron More articles by this author Expand All Advertisement PDF downloadLoading ...
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.007 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".